I wonder If we might get some more news from the SAS scheme. It seems there has been an increase in strep a infections and flesh eating bacteria infections presenting at the murdock childrens hospital. And that seems to be the exact place we established a research unit recently. I believe flesh eating bacteria were even mentioned as having been treated in the recent update although I don't recall if they mentioned Murdoch hospital.
It seems we are starting to slowly edge into actually treating real world infections. The research unit is certainly in the right spot to gain SAS access to these untreatable infections.






Researchers have warned an “intense” surge in flesh-eating Strep A infections in Australia is putting children and the elderly at risk.The Murdoch Children’s Research Institute found the number of kids sent to hospital with the infection rose from 23 in 2020 to 107 in 2022.The common, but deadly, bacteria can cause severe life-threatening infections, including toxic shock syndrome and flesh-eating disease.
https://www.news.com.au/lifestyle/health/researchers-warn-deadly-strep-a-bacteria-surging-amid-push-to-find-a-cure/news-story/c083111d26dd51fb304031c780448fc7

Recce Pharmaceuticals Establishes Anti-Infective Research Unit at Murdoch Children’s Research Institute

Published: Dec 19, 2022

Highlights:

• Recce’s new Anti-Infective Research Unit located within Murdoch Children's world-leading research facilities – internationally recognized for medical research breakthroughs
• Fit-for-purpose laboratory space will be allocated solely to this work within Murdoch Children's – one of the top three children’s research institutes worldwide
• Dedicated Murdoch Children's team with access to infectious disease and other expertise together with millions of dollars in specialist infrastructure to support Recce’s expanding anti-infective pipeline
• Recce will streamline ongoing pre-clinical programs and explore new research development opportunities
• Subsidised collaborative for tackling infectious diseases – cost-efficient studies, laboratory space provided at no additional cost

SYDNEY, Australia, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, today announced the commencement of an Anti-Infective Research (AIR) Unit through the execution of a research collaboration agreement with Murdoch Children’s Research Institute (Murdoch Children's). The agreement secures a dedicated research team of infectious disease experts and fit-for-purpose laboratory space with access to a library of clinical isolates and drug-resistant pathogens.

https://www.biospace.com/article/releases/recce-pharmaceuticals-establishes-anti-infective-research-unit-at-murdoch-children-s-research-institute/